Stevenage Bioscience Catalyst
Dr. Sally Ann Forsyth OBE is an accomplished leader in the life sciences sector, currently serving as Chief Executive Officer at Stevenage Bioscience Catalyst since March 2018, where the focus is on fostering a supportive environment for biotech, pharma, and med-tech businesses. In addition, Dr. Forsyth holds the position of Non Executive Director and Chair of the ESG Committee at Life Science REIT since November 2021. Previously, Dr. Forsyth was Chief Executive Officer at Norwich Research Park, leading its strategic growth and development from September 2013 to March 2018. With a background that includes roles as Director of Science Parks at Goodman International and Director of Colworth Science Park at Unilever, Dr. Forsyth has extensive experience in strategic development and innovation in the life sciences field. Educational qualifications include a PhD in Molecular Biology from the University of Cambridge and an MPhil in Genetics and Molecular Biology.
This person is not in the org chart
This person is not in any teams
Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is a leading location for companies to develop and commercialise cutting edge therapeutics. The Campus is home to major organisations including GSK, the Cell & Gene Therapy Manufacturing Catapult and LifeArc alongside a growing cluster of life sciences start-up companies which together have raised £2.9bn in funding. The facilities have been designed to foster cooperation, scientific and commercial dialogue and interaction between entrepreneurs. Access is offered to business support, equipment and facilities that would otherwise be beyond the reach of small or medium-sized companies.